Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A double overnight, even!!
I notice a British development attacking bacteria quite similar to the approach of NanoViricides toward viruses - attacking, and ripping open the bacterial membrane. BIG news!!! No contempt. Let's get the buying brigade involved!!!
I also see the stock price going up big-time, too.
Nothing in sight/site to keep it down!
Contempt included.
Those were rhetorical question in the faint hope they would have an impact and suggest that this company follow my suggestions!!
Fat chance that!!
Message boards!!!
lol!!!!
But the company might have a remote chance if they follow my suggestions!
I used to get $2,000 for a 5 minute review back in the good old days!!!
But a message board reduces that to 5¢™!!
Buddy, can you spare a dime???
I see NanoViricides coming up roses with Glaxo.
Not yet!!
Won't say publicly! iHub does not appreciate such info posted.
Tried a private message but my level of membership does not permit it.
Send me your email and I will send you the info.
donpatent@gmail.com
Is PTOI producing any resin???
Or styrene??
Or any other of the various plastic building blocks reclaimable from waste plastics????
I wonder when Glaxo will make its move and buyout NNVC.
Will PFHO be buried by blockchain?
If blockchain is, in fact, the linchpin of healthcare to come and PFHO is not using it, I epect PFHO to continue its path to BK.
Ref:
IBM's Watson Health artificial intelligence unit has signed a two-year joint-development agreement with the U.S. Food and Drug Administration (FDA) to explore using blockchain technology to securely share patient data for medical research and other purposes.
IBM's researchers believe that by keeping an audit trail of all transactions on an unalterable distributed ledger, blockchain technology establishes accountability and transparency for data exchange.
"Transformative healthcare solutions are possible when healthcare researchers and providers have access to a 360-degree view of patient data. Today, patients have little access to their health data and cannot easily share with researchers or providers," IBM said.
IBM recently surveyed 200 healthcare executives, both with insurance payers and medical providers, and found 16% expect to have a commercial blockchain service at scale in 2017 for sharing data securely.
....
Research has found that using patient data with machine-learning algorithms can drastically improve both the cost and quality of healthcare through simulation modeling.
"Giving patients the opportunity to share their data securely, for research purposes or across their healthcare providers, would create opportunities for major advancements in healthcare," IBM and the FDA said in a joint statement.
The two plan to look at how a blockchain framework can aid public health by supporting important use cases for information exchange across a wide variety of data types, including clinical trials and "real world" data.
Patient data from mobile devices, wearables and other connected devices, for example, can help doctors and caregivers better manage population health, according to IBM.
IBM brings extensive expertise in blockchain technology. For example, IBM is a founding member and key contributor to the Linux Foundation's Hyperledger project. For its part, IBM will work to define and build a scalable and decentralized data sharing ecosystem.
IBM Watson Health and the FDA plan to publicize initial findings in the use of blockchain for healthcare data sharing later this year.
https://www.computerworld.com/article/3156504/healthcare-it/ibm-watson-fda-to-explore-blockchain-for-secure-patient-data-exchange.html
https://www.coindesk.com/cdc-trial-blockchain-ibm-bid-manage-medical-data/
With NNVC approaching FDA review I find this applicable and appropriate, perhaps; after all, the FDA review is all about data, test patients and results:
IBM Watson, FDA to explore blockchain for secure patient data exchange
The initial focus for blockchain will be oncology-related data exchange
Lucas Mearian By Lucas Mearian
Senior Reporter, Computerworld | JAN 11, 2017 5:01 AM PT
IBM's Watson Health artificial intelligence unit has signed a two-year joint-development agreement with the U.S. Food and Drug Administration (FDA) to explore using blockchain technology to securely share patient data for medical research and other purposes.
IBM Watson Health and the FDA will explore the exchange of patient-level data from several sources, including electronic medical records (EMRs), clinical trials, genomic data, and health data from mobile devices, wearables and the "Internet of Things." The initial focus will be on oncology-related information.
....
IBM's researchers believe that by keeping an audit trail of all transactions on an unalterable distributed ledger, blockchain technology establishes accountability and transparency for data exchange.
"Transformative healthcare solutions are possible when healthcare researchers and providers have access to a 360-degree view of patient data. Today, patients have little access to their health data and cannot easily share with researchers or providers," IBM said.
IBM recently surveyed 200 healthcare executives, both with insurance payers and medical providers, and found 16% expect to have a commercial blockchain service at scale in 2017 for sharing data securely.
....
Research has found that using patient data with machine-learning algorithms can drastically improve both the cost and quality of healthcare through simulation modeling.
"Giving patients the opportunity to share their data securely, for research purposes or across their healthcare providers, would create opportunities for major advancements in healthcare," IBM and the FDA said in a joint statement.
The two plan to look at how a blockchain framework can aid public health by supporting important use cases for information exchange across a wide variety of data types, including clinical trials and "real world" data.
Patient data from mobile devices, wearables and other connected devices, for example, can help doctors and caregivers better manage population health, according to IBM.
IBM brings extensive expertise in blockchain technology. For example, IBM is a founding member and key contributor to the Linux Foundation's Hyperledger project. For its part, IBM will work to define and build a scalable and decentralized data sharing ecosystem.
IBM Watson Health and the FDA plan to publicize initial findings in the use of blockchain for healthcare data sharing later this year.
https://www.computerworld.com/article/3156504/healthcare-it/ibm-watson-fda-to-explore-blockchain-for-secure-patient-data-exchange.html
https://www.coindesk.com/cdc-trial-blockchain-ibm-bid-manage-medical-data/
Ebadollahi said that that the effort is an extension of the tech giant's (IBM) existing research initiative with the U.S. Food and Drug Administration (FDA). Announced earlier this year, that initiative with the FDA is aimed at testing a blockchain-based platform through which electronic medical records, clinical trials, and health data gathered from wearable devices could be better shared.
....
Ebadollahi believes that blockchain and AI are on the verge of revolutionizing healthcare globally. “When a bunch of physicists collaborated and created this thing called the World Wide Web a few decades ago, nobody imagined Facebook and Google and Amazon,” he said. “With blockchain we can collect data and extract insights through AI, and the future will have an economy around that we can hardly even imagine right now.”
https://www.fastcompany.com/40481883/ibm-watson-health-is-teaming-up-with-the-cdc-to-research-blockchain
The Food and Drug Administration’s Office of Innovation is looking for an enterprise blockchain solution that can meet the needs of use cases agencywide. Steven Hubbard, the office’s senior technical adviser, said the technology has potential to help the agency securely exchange the data it receives faster — including adverse event data or regulation packages that require review.
Leveraging the cloud is also part of FDA’s strategic plan, from infrastructure to platform-as-a-service. For the Office of Innovation, that means sandboxing ideas to figure out how to get certain solutions to meet FDA’s needs, faster.
http://governmentciomagazine.com/exploring-blockchain-future-fda-data-exchange
I know the shills I follow by name/Nick and follow their travels here and there on the yellow brick road they travel in their pursuit of easy money.
They have a history of one loser after another.
I'll keep at it till my DD proves that paid shills are death to those duds they are hired to promote!
Not wrong, yet!!
Talk about foolproof!!!!
At $5 zyxi looks like a great short winner!
Pennies soon...from heaven.
That 539% recommendation is noted.
Looks like a guaranteed winner here.
Investing in any company that hires paid shills to move their stock is not wise.
Recycle in a loop is the only way!!
Use the "waste" as feedstock to make new virgin plastic (must contact Richard Branson!!).
End of waste, period!
No problem, just turn that waste into a profitable feedstock.
I'm thinking out loud, now, but I figure after all is considered to date we need a full blood transfusion after 13 years, new blood, younger blood and a vigorous shakeup to get us to $100 where we belong.
A new CEO and a new COO.
It's time (13 years!!!!)!
Let's vote!!
Any suggestions?
Meeta is my choice for CEO!
COO?
No clue.
And blockchain front and centre!!
Good grief, yes, me, I own the company!
You won't get better than that.
Owners count.
The tech stinks!
I try to suggest a remedy.
So I get ignored!!
Welcome to my world.
Resin is key, anything else is history.
Resin is the future.
We need new blood! A new attack. Anything.
The old blood got us here - we need new blood to double and triple overnight where this technology should (!!!!) be taking us.
I know a triple/double overnight is not everybody's cup of tea.
I'd just like to try!
Drink up.
Excellent Results in Inhibiting Shingles Virus in Human Skin: NanoViricides Extends Agreement with SUNY Upstate Medical Center
https://www.prnewswire.com/news-releases/excellent-results-in-inhibiting-shingles-virus-in-human-skin-nanoviricides-extends-agreement-with-suny-upstate-medical-center-300543762.html
NanoViricides and Glaxo - what is the connection there?
This is "One step at a time" in action!
Just imagine what would happen with blockchain in the equation!
This Heddle Marine is no lightweight - I note that!
And if Heddle is as smart as I know he is, he will direct his plastic wate handling equipment to making resin, not oil or fuel.
Resin, I note, is the only way to go!!
I rest my case!
Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates
Published: Dec 6, 2017 7:00 a.m. ET
SHELTON, Conn., Dec. 6, 2017 /PRNewswire/ -- NanoViricides, Inc. (nyse mkt:NNVC) (the "Company") reports that it has begun initial safety and toxicology evaluation of its optimized nanoviricides® drug candidates developed against varicella-zoster virus (VZV), the shingles virus. This study is an important step in the drug development pathway for a treatment for shingles, a debilitating infection of human skin by VZV. The long term goal of this project is the development of nanoviricide drugs for topical dermal treatment of shingles, genital herpes and cold sores.
The non-GLP safety and toxicology study in rats is being conducted at AR Biosystems, Beverly, MA. The study will (i) evaluate the direct effects of topical delivery of the drug candidates on the skin, (ii) assess if the drugs attain detectable levels in the blood, and also (iii) evaluate whether there are any effects on the blood and primary organs, in uninfected animals. The results of this study will provide the basis and focus for the IND-enabling GLP safety and toxicology studies that are required for the IND submission to the U.S. FDA. As a result of the success of its drug lead optimization process, the Company has selected two clinical development candidates for further evaluation in this initial safety/toxicology study.
The Company has previously reported that the nanoviricides® drug candidates showed marked inhibition of VZV infection, replication and spread in human skin cultured ex vivo in experiments performed in the laboratory of Dr. Jennifer Moffat, SUNY Upstate Medical Center. Since VZV causes skin lesions, experimental VZV infection of human skin is considered to be representative of natural VZV infection. VZV is restricted to human tissue and only infects and replicates in human tissue. Dr. Moffat runs a leading laboratory studying disease-relevant models of VZV infection of human skin for evaluating effectiveness of potential drugs against the shingles virus.
The market size for anti-shingles drugs is currently estimated to be in the range of billions of dollars, even though shingles vaccines are available.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
View original content with multimedia:http://www.prnewswire.com/news-releases/nanoviricides-initiates-a-safetytoxicology-study-of-its-leading-shingles-candidates-300567483.html
SOURCE NanoViricides, Inc.
Copyright (C) 2017 PR Newswire. All rights reserved
If it ain't broke don't fix it.
When one or the other takes over both I will take notice.
Right now there is nothing to notice.
Would be a neat way for Heddle Marine to go public!!
NNVC will succeed with or without blockchain, except with blockchain the success will come overnight and not 2 years from now.
I prefer the overnight version.
I rest my case!!
And these ICO tokens/coins/rights/warrants are not just for existing shareholders, they are for those who would wish to be so in 1 - 5 years or so!
I see blockchain as an assistant to share ownership not as a replacement for it.
However, if and when a replacement is necessary, so be it.
The gems are sparkling still but the shills hired to polish them failed badly.
You get what you pay for!
What I like best about blockchain is the clear fact that the NNVC shorts don't have the slightest clue about it and will lose their shirts trying to capitalize on it.
Worth plenty!
But (!!!!) everybody is getting in on this broad spectrum flu vaccine business:
http://www.siliconinvestor.com/readmsg.aspx?msgid=31451478
Must not dawdle!!!!!!!!!
I did buy NNVC and now to educate Buffett on it and Blockchain!!!
I like the internet....now that it is up and running....great.
When first mentioned I liked the concept!
Same with blockchain now...I like the concept.
Grab it and run with it.
Make some cold hard cash in the process!!
Win, win.
In the interest of necessity and to save lives being lost daily as flu decimates the populations, will the FDA speed up approval?
There are such provisions!
Ref:
http://www.latimes.com/science/sciencenow/la-sci-sn-fda-expedited-drugs-20171205-story.html
I like the concept of being first in line be it for a concert ticket or for consideration of a sublicense for the drug of the century.
Such line jumping is a valuable asset for any big biopharm interested in having a piece of the future drug blockbuster (by blockchain)!
I note, just in passing, that Inovio (full disclosure - I own it, too) has announced their broad spectrum DNA antigen vaccine provides full protection against any and all flu variations.
Brilliant!!
For those not vaccinated and with FDA approval, NNVC's FluCide will provide relief for those infected.
Ref:
http://ir.inovio.com/news-and-media/news/press-release-details/2018/Inovio-Pharmaceuticals-Published-Universal-Flu-Vaccine-Data-Demonstrates-Protective-Responses-Against-All-Major-Lethal-H1N1-Influenza-Viruses-From-the-Last-100-Years-in-Animal-Models/default.aspx
BTW, I look upon these "others" as encouraging - it indicates to me, at least, that NanoViricides is onto something very valuable and is leading the field.
Now, with Blockchain lurking in the background and the investing public looking, as always, for the next best thing, the future for NNVC looks bright and with FDA approval, BLOODY BRILLIANT!
Just looking positive!!
Allegedly.
**OTHERS using this virus trapping tech:
ExThera
GL Hendricks
Modulating Influenza and Heparin Binding Viruses' Pathogenesis with Extrinsic Receptor Decoy Liposomes - eScholarship@UMMS
PDFescholarship.umassmed.edu › viewcontent
by GL Hendricks · 2013 · Related articles
Jun. 28, 2013 · Heparin sulfate decoy liposomes inhibit respiratory syncytial virus and herpes simplex virus. Preface . ...... infectious titer by trapping budding virus onto infected cell surfaces. Non-neutralizing anti-NP.
**Liposomal Decoys Capture Influenza A Virus
Background: Better treatments are needed for combating influenza.
Results: LSTc-sialoside-bearing decoy liposomes competitively bind to influenza A virus, as assessed by hemagglutination inhibition, flow cytometry, and growth inhibition studies. Decoy liposomes co-localize with influenza virus, as assessed by confocal imaging.
Conclusion: LSTc-sialoside-bearing decoy liposomes are highly effective in capturing influenza virus.
Significance: Decoy liposomes may serve as an effective platform for presenting anti-pathogen receptors.
Abstract
Influenza is a severe disease in humans and animals with few effective therapies available. All strains of influenza virus are prone to developing drug resistance due to the high mutation rate in the viral genome. A therapeutic agent that targets a highly conserved region of the virus could bypass resistance and also be effective against multiple strains of influenza. Influenza uses many individually weak ligand binding interactions for a high avidity multivalent attachment to sialic acid-bearing cells. Polymerized sialic acid analogs can form multivalent interactions with influenza but are not ideal therapeutics due to solubility and toxicity issues. We used liposomes as a novel means for delivery of the glycan sialylneolacto-N-tetraose c (LSTc). LSTc-bearing decoy liposomes form multivalent, polymer-like interactions with influenza virus. Decoy liposomes competitively bind influenza virus in hemagglutination inhibition assays and inhibit infection of target cells in a dose-dependent manner. Inhibition is specific for influenza virus, as inhibition of Sendai virus and respiratory syncytial virus is not observed. In contrast, monovalent LSTc does not bind influenza virus or inhibit infectivity. LSTc decoy liposomes prevent the spread of influenza virus during multiple rounds of replication in vitro and extend survival of mice challenged with a lethal dose of virus. LSTc decoy liposomes co-localize with fluorescently tagged influenza virus, whereas control liposomes do not. Considering the conservation of the hemagglutinin binding pocket and the ability of decoy liposomes to form high avidity interactions with influenza hemagglutinin, our decoy liposomes have potential as a new therapeutic agent against emerging influenza strains.
Authors
Gabriel L. Hendricks‡, Kim L. Weirich§, Karthik Viswanathan¶, Jing Li¶, Zachary H. Shriver¶, Joseph Ashour?, Hidde L. Ploegh?, Evelyn A. Kurt-Jones‡, Deborah K. Fygenson§, **, Robert W. Finberg‡, James C. Comolli‡‡,1 and Jennifer P. Wang‡,2From the ‡Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605,§Biomolecular Science and Engineering Program,**Department of Physics, University of California, Santa Barbara, California 93106,the ¶Department of Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139,?Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, and‡‡Charles Stark Draper Laboratory, Department of Bioengineering, Cambridge, Massachusetts 02139 ?2 To whom correspondence should be addressed: Dept. Medicine, University of Massachusetts Medical School, 364 Plantation St., Worcester, MA 01605. Tel.: 508-856-8414; Fax: 508-856-6176;
E-mail: Jennifer.Wang@umassmed.edu.
m.jbc.org
**Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism
Valeria Cagno, Patrizia Andreozzi, Marco D’Alicarnasso, Paulo Jacob Silva, Marie Mueller, Marie Galloux, Ronan Le Goffic, Samuel T. Jones, Marta Vallino, Jan Hodek, Jan Weber, Soumyo Sen, Emma-Rose Janecek, Ahmet Bekdemir, Barbara Sanavio, Chiara Martinelli, Manuela Donalisio, Marie-Anne Rameix Welti, Jean-Francois Eleouet, Yanxiao Han, Laurent Kaiser, Lela Vukovic, Caroline Tapparel, Petr Král, Silke Krol, David Lembo & Francesco Stellacci
An international research team including Petr Kral, a UIC professor of chemistry, has developed innovative anti-viral nanoparticles with the ability to bind to a range of viruses such as respiratory syncytial virus, herpes simplex virus, Dengue and Lentiviruses, and human papillomavirus. In contrast to other broad-spectrum antivirals, which just restrict viruses from infecting cells, the nanoparticles developed by the team have the ability to destroy viruses.
Kral and his team, which comprised assistant professor of chemistry Lela Vukovic from the University of Texas at El Paso who was an author on the paper, endeavored to develop an innovative anti-viral nanoparticle based on HSPG, yet one that will get attached more tightly to viral particles and kill them simultaneously.
A Swiss National Science Foundation NRP 64 grant, the National Centers of Competence in Research on Bio-Inspired Materials, the University of Turin, the Ministry of Education, Youth and Sports of the Czech Republic, the Leenards Foundation, National Science Foundation award DMR-1506886, and funding from the University of Texas at El Paso supported the study.
.
.
**CONCLUSION
There are only two companies bringing this ligand virus binding technology to market; ExThera in a blood filtering system; NanoViricides in a drug, be it by mouth, injection or topical application. Both are following the FDA path to approval.
U.S. Food and Drug Administration (FDA) has granted ExThera’s Seraph® 100 Blood Filter (Seraph) the agency’s Expedited Access Pathway (EAP)
http://www.siliconinvestor.com/subject.aspx?subjectid=59762
I have no idea - ask management.
BTW, their focus at the moment is HerpesCide approval by the FDA. I expect some comment from HQ soon on that and when significant.
IMHHO.